Clinical Trials Logo
  1. Home
  2. Birch Pollen Allergy
  3. NCT04266028

Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

Birch Pollen Allergy Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Subcutaneous Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

Clinical Trial Summary

Randomized, double-blind placebo-controlled phase I study to investigate the safety and tolerability of ascending doses of DM-101 in adult subjects with birch pollen allergy.

Clinical Trial Description

The study will be carried out in a single study site located in Finland. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04266028
Study type Interventional
Source Desentum Oy
Contact
Status Completed
Phase Phase 1
Start date February 11, 2020
Completion date May 31, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT06037148 - Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants Phase 1
Completed NCT04912076 - S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen Phase 1
Recruiting NCT05346718 - Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis N/A
Completed NCT01137357 - Probiotics for Reduction Of Markers In Subjects With Allergy N/A
Active, not recruiting NCT05668390 - Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma Phase 3
Not yet recruiting NCT02146300 - Effect of the Nasal Provocation on the Breathing Style N/A
Completed NCT01449786 - Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy Phase 2
Completed NCT03969849 - Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants Phase 1
Completed NCT04435678 - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens N/A
Completed NCT01628484 - Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation Phase 1
Completed NCT00932607 - SUBLIVAC® Birch PROBE Study Phase 2
Completed NCT00266526 - Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV Phase 2
Completed NCT02143583 - Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment Phase 2
Completed NCT02074930 - Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure N/A
Completed NCT00309062 - Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis Phase 3
Completed NCT01675791 - A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet Phase 2